As part of the initial phase of this partnership, U.S. healthcare providers can now order the Galleri test directly through Quest Diagnostics’ connectivity system, integrating the test into Quest’s Quanum laboratory portal and over 900 electronic health record (EHR) systems.
With more than 500,000 providers using Quest’s ordering system last year, the collaboration aims to simplify the process for physicians and increase patient access. Patients with a physician’s order can now visit any of Quest’s 7,400 patient access points nationwide without needing to bring a separate test kit to their appointment.
The Galleri test detects cancer by analysing DNA fragments in the bloodstream, identifying unique cancer “fingerprints” even before symptoms appear. Designed for adults at elevated risk for cancer, such as those aged 50 and older, the test screens for multiple hard-to-detect cancers that currently have no recommended screening protocols. It also provides insights into the likely origin of detected cancer signals, helping doctors make informed decisions on further testing and care.
The partnership marks a significant step forward in expanding early cancer detection capabilities and improving accessibility for both providers and patients across the United States.
“Quest Diagnostics and GRAIL share a commitment to improving access to cancer screening and have worked productively together to enable patient access to GRAIL’s Galleri test via Quest’s phlebotomy network since 2021,” said Mark Gardner, Senior Vice President, Molecular Genomics and Oncology for Quest Diagnostics.
“Integrating GRAIL’s Galleri test into the Quest connectivity system is the next step in this collaboration. We expect it to increase patient access by giving Quest’s provider clients the ability to seamlessly order the test through Quest, same as they do for other blood work. This collaboration brings to life the tremendous value of Quest’s ability to scale diagnostic innovation to make it accessible for all.”
“We know every minute counts for busy providers, their staff and their patients, which is why we’re so pleased to work with Quest to offer a seamless experience that fits into providers’ existing ordering process,” commented Josh Ofman, MD, MSHS, President at GRAIL.
He added: “While today there are recommended screenings for five cancers, nearly 70% of deaths are caused by cancers with no recommended screening test. We believe this integration will help to make it easier to incorporate the Galleri test into routine exams to help screen for cancer before it becomes symptomatic when outcomes may be improved.”
